Randomized period: the total duration will be up to approximately of 20 months (1 month screening 18 months of treatment and a possible follow-up period of 1 month if no participation in the long-term extension period)~Long-term extension period: the total duration will be approximately 19 months (18 months of treatment and 1 month of follow-up period)
This is an 18-month, multicenter, randomized, active-control, parallel-group Phase 3 study, in which participants will be randomized to venglustat versus standard of care therapy (agalsidase alfa, agalsidase beta, or migalastat) to evaluate the effect of venglustat on left ventricular mass index (LVMI) in adult participants with Fabry disease and left ventricular hypertrophy.~Study visits will take place approximately every 3 to 6 months~Participants who complete the randomized period may continue to the long-term extension (LTE) to receive venglustat for up to an additional 18 months.